To determine if upregulation of this transporter was important to patient outcome in LUAD, we assessed the levels of SLC7A5 in three LUAD datasets; BCCRC (n = 77 pairs), TCGA RNA-seq (n = 562; 503 tumor, 59 non-malignant), and KMplotter (n = 720 tumor) (Table 1). This evidence concerns the gene SLC7A5 and neoplasm.